- US12539303utility2026RET Inhibitor for Use in Treating Cancer Having a RET Alteration0 cites
- US12459941utility2025Tricyclic IRAK Inhibitors0 cites
- US12448366utility2025Solid Forms of Pralsetinib0 cites
- US12441723utility2025Pyrazole Compounds, Formulations Thereof, and a Method for Using the Compounds And/or Formulations0 cites
- US12384775utility2025Pyrimid-2-yl-pyrazole Compounds as IRAK Inhibitors0 cites
- US12357623utility2025Method for Treating a Disease or Condition Using a Pyrazole Compound or Formulation Thereof0 cites
- US12331036utility2025Heterocyclic RIP1 Kinase Inhibitors0 cites
- US12297202utility2025RIP1K Inhibitors0 cites
- US12263180utility2025Method for Treatment of Covid-19-associated Conditions0 cites
- US12227508utility2025Tgf-β Inhibitors0 cites
- US12156880utility2024Heterocyclic RIP1 Kinase Inhibitors0 cites
- US12116354utility2024RIP1 Inhibitory Compounds and Methods for Making and Using the Same0 cites
- US12043620utility2024Benzazole Compounds and Methods for Making and Using the Compounds0 cites
- US12043629utility2024RIP1K Inhibitors0 cites
- US11993594utility2024IRAK Inhibitors and Method for Making and Using0 cites
- US11963958utility2024RET Inhibitor for Use in Treating Cancer Having a RET Alteration0 cites
- US11939317utility2024Amide Compounds and Method for Making and Using0 cites
- US11827628utility2023Compositions and Methods for Inhibition of the JAK Pathway0 cites
- US11672791utility2023Tyrosine Kinase Inhibitors0 cites
- US11667611utility2023Compositions and Methods for Inhibition of the JAK Pathway0 cites
Page 1 of 2Next →